Amadeus Capital Partners is one of Europe's pioneering deep-tech venture firms — investing since 1997 in what it calls "trailblazers solving hard problems in large markets." The thesis organises deep technology into three domains: Intelligence (AI, advanced computing, quantum), Human (health, medicine, wellness) and Planet (sustainability, energy, novel materials, space utilisation), investing from seed to growth across the UK, Europe and select global opportunities (amadeuscapital.com).
Longevity is the differentiator. Few firms have done deep tech continuously for nearly three decades, through cycles when the category was deeply unfashionable. That history shows in the portfolio: the firm has backed more than 200 companies and taken 17 to IPO — a record of technical judgment compounded over time, not a recent rebrand into AI.
On stage and sector, Amadeus invests from seed to growth in deep technology: AI, quantum, semiconductors, healthtech, space and sustainability. The geographic centre is the UK and Europe, with select investments globally. The firm looks for hard technical problems in large markets — the kind of companies where diligence requires scientists, not just spreadsheets.
On size, the firm's homepage states it has "raised over $1.3 billion for investment" — the figure this profile uses. Individual historical fund sizes are only partially disclosed on the site's timeline (the first fund was £50 million), so this profile states the aggregate as published rather than reconstructing vintages.
The portfolio is a deep-tech hall of fame. Verified names from the official site's portfolio and timeline include Oxford Nanopore Technologies, Paragraf, Healx, Altana AI, Nu Quantum, Ori Biotech, OrganOx and Ravelin — alongside landmark exits: VocalIQ (acquired by Apple), Solexa (acquired by Illumina) and CSR, Cambridge Silicon Radio. From gene sequencing to quantum hardware to speech AI, the common thread is genuine technical difficulty.
Leadership is founder-led after nearly three decades: Anne Glover is chief executive and co-founder, and Hermann Hauser — the Cambridge technology legend — is co-founder (official site: "Anne and Hermann raise the first £50m fund"). Professor Steve Young is noted as a venture partner on the official timeline. It is a partnership built around technical authority.
Two firm initiatives stand out. The Amadeus APEX Technology Fund — an €80 million target vehicle with a €28 million first close, run in partnership with APEX Ventures for European deep tech (announced 2023, official site timeline). And AUGMENT, a global collaboration programme with UTEC (University of Tokyo Edge Capital Partners) to accelerate deep-tech startups between Europe and Japan (UTEC official announcement) — a genuine cross-border platform for portfolio companies eyeing Asian expansion.
No portfolio credit or perks programme was verified. The firm's value-add is technical judgment, a three-decade network across European science and industry, and — through AUGMENT — a bridge to Japan. For deep-tech founders, that combination is rare: an investor that can evaluate the science, fund it from seed to growth, and open doors in two continents' industrial ecosystems.
Why it matters for founders
Amadeus is where European deep tech goes for investors who understand the technology. Nearly three decades, over $1.3 billion raised, 17 IPOs — and programmes like AUGMENT that connect European startups to Japan. If your advantage is technical and your timeline is long, this is the investor built to match both.